Brain Cancer Awareness Month: Vaccine confers benefit, AI identifies potential targets
Click Here to Manage Email Alerts
May is Brain Cancer Awareness Month.
An estimated 24,810 new cases of brain cancer and other nervous system cancers will be diagnosed this year in the United States, according to SEER data.
Approximately 18,990 people will die of those tumors this year, accounting for 3.1% of all cancer deaths in the nation, SEER estimates suggest.
In conjunction with Brain Cancer Awareness Month, Healio provides the following updates on neuro-oncology research and treatment advances.
1. The addition of disulfiram and copper to chemotherapy did not result in a significant survival benefit for patients with recurrent glioblastoma. Read more.
2. The use of low-intensity pulsed ultrasound with concomitant administration of IV microbubbles can improve the delivery of albumin-bound paclitaxel and carboplatin through the blood-brain barrier. Read more.
3. The addition of DCVax-L (Northwest Therapeutics) — an autologous tumor lysate-loaded dendritic vaccine — to standard care extended OS among certain patients with glioblastoma. Read more.
4. Maximal resection of low-grade glioma shortly after diagnosis may lead to longer survival. Read more.
5. Vorasidenib (Servier) conferred statistically significant and clinically meaningful improvements in PFS and time to next intervention for patients with residual or recurrent IDH-mutant low-grade glioma. Read more.
6. Researchers have developed an implantable, pressurized pump to circumvent the blood-brain barrier and direct chemotherapy to the location of recurrent glioblastoma tumors. Read more.
7. Researchers developed an artificial intelligence algorithm that uses computational analysis to identify possible therapeutic targets for glioblastoma multiforme and other types of cancer. Read more.
8. The FDA approved dabrafenib (Tafinlar, Novartis) with trametinib (Mekinist, Novartis) for children with previously untreated low-grade glioma who harbor BRAF V600E mutations and require systemic therapy. Read more.
9. Tovorafenib (Day101, Day One Biopharmaceuticals) monotherapy induced response among approximately two-thirds of patients with recurrent or progressive pediatric low-grade glioma. Read more.
Reference:
- NCI. Cancer stat facts: brain and other nervous system cancer. Available at: https://seer.cancer.gov/statfacts/html/brain.html. Accessed May 8, 2023.
Collapse
Healio Coverage
Click Here to Manage Email Alerts